SBOSS E-BROCHURE ACCESS VIRTUAL PLATFORM - 8 JANUARY, 2021 VIRTUAL SUMMIT 9-10 JANUARY, 2021 VIRTUAL SUMMIT - apbcs
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
8 JANUARY, 2021
VIRTUAL SUMMIT
SUPPORTED BY:
9-10 JANUARY, 2021
VIRTUAL SUMMIT
ACCESS
VIRTUAL PLATFORM
SBOSS E-BROCHURE
ORGANIZED BY
APBCS.ORG
1TABLE OF
CONTENT
Scientific Committee 3
Speakers 4
Agenda 6
Sponsors 8
2SCIENTIFIC COMMITTEE
GEOK HOON LIM
SINGAPORE
VERONIQUE TAN
SINGAPORE
3SPEAKERS
BENITA TAN
SENIOR CONSULTANT, NATIONAL CANCER CENTRE SINGAPORE (NCCS)
SINGAPORE
CHAN CHING WAN
ASSOCIATE PROFESSOR, NATIONAL UNIVERSITY HOSPITAL
SINGAPORE
CHI WEI MOK
CONSULTANT SURGEON, CHANGI GENERAL HOSPITAL
SINGAPORE
FAYE LIM
SENIOR CONSULTANT, NATIONAL CANCER CENTRE SINGAPORE (NCCS)
SINGAPORE
GALE LIM
HEAD AND CONSULTANT FOR THE DEPARTMENT OF PLASTIC,
RECONSTRUCTIVE SURGERY, KK WOMEN’S & CHILDREN’S HOSPITAL
SINGAPORE
GEOK HOON LIM
HEAD AND SENIOR CONSULTANT OF BREAST DEPARTMENT
KK WOMEN’S AND CHILDREN’S HOSPITAL
SINGAPORE
4GERALD GUI
CONSULTANT BREAST SURGEON, THE ROYAL MARSDEN
UNITED KINGDOM
JULIANA CHEN
SENIOR CONSULTANT, TAN TOCK SENG HOSPITAL
SINGAPORE
PHILIP POORTMANS
PROFESSOR, CURIE INSTITUTE
BELGIUM
TIRA TAN
CONSULTANT, DIVISION OF MEDICAL ONCOLOGY
NATIONAL CANCER CENTRE SINGAPORE (NCCS)
SINGAPORE
VERONIQUE TAN
HEAD & SENIOR CONSULTANT BREAST SURGERY
NATIONAL CANCER CENTRE SINGAPORE (NCCS)
SINGAPORE
YEE SIANG ONG
PLASTIC AND RECONSTRUCTIVE SURGEON, SINGAPORE GENERAL HOSPITAL
SINGAPORE
5Friday, 8th January 2021
AGENDA 18:00 - 20:35 Singapore Time
18:00 – 18:05 Opening Remarks
GEOK HOON LIM, SINGAPORE
Chairperson: CHING WAN CHAN, SINGAPORE
18:05 – 18:20 Prepectoral or subpectoral implant- when to do which? and how I do my prepectoral implant
reconstruction
GERALD GUI, UK
18:20 – 18:25 Q&A
Chairperson: Gale Lim, Singapore
18:25 – 18:40 ALCL- are implants still safe to use? What advice do we give to our patients?
YEE SIANG ONG, SINGAPORE
18:40 – 18:45 Q&A
Roche Symposium - Chairperson: Faye Lim, Singapore
18.45 – 19.15 A Multidisciplinary Approach to Neoadjuvant Therapy in Aggressive Breast Cancer
VERONIQUE TAN, SINGAPORE ; TIRA TAN, SINGAPORE
19:15 – 19:20 Q&A
Chairperson: Faye Lim, Singapore
19:20 – 19:35 What surgeons need to know about preoperative radiation therapy?
PHILIP POORTMANS, BELGIUM
19:35 – 19:40 Q&A
Chairperson: Benita Tan, Singapore
19:40 – 19:55 An update on Endoscopic / Robotic Breast Surgery
CHI WEI MOK, SINGAPORE
19:55 – 20:00 Q&A
Chairperson: Juliana Chen, Singapore
20:00 – 20:15 Tips and Tricks on Nipple Sparing Mastectomy in Women with Large and Ptotic Breast
GERALD GUI, UK
20:15 – 20:20 Q&A
20:20 – 20:35 Case discussion
ALL
20:35 Closing Remark
GEOK HOON LIM, SINGAPORE
6TREAT
HER
EARLY
Neoadjuvant PERJETA-Herceptin
plus chemotherapy*: part of a
complete, efficacious treatment
regimen for HER2-positive eBC
in the curative setting1,2
Indication for neoadjuvant treatment:
PERJETA is indicated for use in combination with Herceptin and chemotherapy in the neoadjuvant treatment
of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk
of recurrence.
eBC=early breast cancer; FEC=5-fluorouracil + epirubicin + cyclophosphamide; HER2=human epidermal growth factor receptor 2; PH=PERJETA-Herceptin.
*Studied options in the registrational trials included PH + docetaxel (4 cycles) (NeoSphere); PH + docetaxel + carboplatin (6 cycles); FEC (3 cycles) followed by PH + docetaxel (3 cycles), PH + FEC (3 cycles) followed by
PH + docetaxel (3 cycles) (TRYPHAENA).1,3,4
There is insufficient evidence to recommend concomitant administration of an anthracycline with PERJETA.
References: 1. PERJETA® Summary of Product Characteristics. F. Hoffmann-La Roche Ltd, Basel, Switzerland, 2017. 2. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast
cancer: the CTNeoBC pooled analysis [published online February 14, 2014]. Lancet. 2014;384:164-172. doi:10.1016/ S0140-6736(13)62422-8. 3. Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab
and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25-32. 4. Schneeweiss A, Chia S, Hickish
T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase
II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24:2278-2284.
Perjeta® (pertuzumab) – Abbreviated Prescribing Information
Before prescribing Perjeta, please consult the full local prescribing information.
THERAPEUTIC INDICATIONS: Metastatic breast cancer: Perjeta is indicated for use in combination with Herceptin and docetaxel for the treatment of adult patients with HER2-positive metastatic or locally recurrent
unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. Early breast cancer: Perjeta is indicated for use in combination with Herceptin and chemotherapy
for the 1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for
early breast cancer, and 2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. POSOLOGY AND METHOD OF ADMINISTRATION: Perjeta is subject to restricted medical prescription
and therapy should only be initiated under the supervision of a physician experienced in the administration of anti-cancer agents. Perjeta should be administered by a healthcare professional prepared to manage anaphylaxis and
in an environment where full resuscitation service is immediately available. Patients treated with Perjeta must have HER2-positive tumour status, defined as a score of 3+ by immunohistochemistry (IHC) and/or a ratio of ≥ 2.0 by
in situ hybridisation (ISH) assessed by a validated test. To ensure accurate and reproducible results, the testing must be performed in a specialised laboratory, which can ensure validation of the testing procedures. DOSAGE
FORMS AND STRENGTHS: 420 mg/14 mL vial. CONTRAINDICATIONS: Perjeta is contraindicated in patients with known hypersensitivity to pertuzumab or to any of its excipients. SPECIAL WARNINGS AND PRECAUTIONS
FOR USE: • Left ventricular dysfunction: The incidence of symptomatic left ventricular systolic dysfunction (LVSD [congestive heart failure]) was higher in patients treated with Perjeta in combination with Herceptin and
chemotherapy compared with Herceptin and chemotherapy. Patients who have received prior anthracyclines or prior radiotherapy to the chest area may be at higher risk of decreased LVEF. • Infusion-related reactions: Perjeta
has been associated with infusion-related reactions including events with fatal outcomes. Close observation of the patient during and for 60 minutes after the first infusion and during and for 30-60 minutes after subsequent
infusions is recommended following the administration of Perjeta. • Hypersensitivity reactions/anaphylaxis: Severe hypersensitivity reactions, including anaphylaxis and events with fatal outcomes have been observed in patients
treated with Perjeta. Medications to treat such reactions, as well as emergency equipment, should be available for immediate use. • Febrile neutropenia: Patients treated with Perjeta, Herceptin and docetaxel are at increased risk
of febrile neutropenia compared with patients treated with placebo, Herceptin and docetaxel, especially during the first 3 cycles of treatment. Symptomatic treatment for mucositis and diarrhoea should be considered.
UNDESIRABLE EFFECTS: The safety of Perjeta has been evaluated in more than 6000 patients in Phase I-III trials and was generally consistent across studies. As Perjeta is used with Herceptin and chemotherapy, it is difficult to
ascertain the causal relationship of an adverse event to a particular drug. The most common ADRs (adverse drug reactions) (≥30%) from pooled data were diarrhea, alopecia, nausea, fatigue, neutropenia and vomiting. The most
common NCI-CTCAE Grade 3-4 ADRs (≥10%) were neutropenia and febrile neutropenia. ENHANCED SAFETY REPORTING FOR POTENTIAL PERJETA-EXPOSED PREGNANCIES: Perjeta should be avoided during pregnancy
unless the potential benefit for the mother outweighs the potential risk to the foetus. There are no studies of Perjeta in pregnant women and the safe use of Perjeta during pregnancy and lactation has not been established. Verify
pregnancy status prior to the initiation of Perjeta. Women of child bearing potential including those who are partners of and male patients should use effective contraception while receiving Perjeta and for 6 months following
the last dose of Perjeta. Monitor patients who become pregnant during Perjeta therapy or within 6 months following the last dose of Perjeta closely for oligohydramnios. If Perjeta is used during pregnancy or if a patient becomes
pregnant while being treated with Perjeta or within 6 months following the last dose of Perjeta, immediately report exposure to the local Roche Adverse Event email at singapore.drugsafety@roche.com or call (65) 6735 0550.
Additional information will be requested during a Perjeta-exposed pregnancy and the first year of the infant’s life. This will enable Roche to better understand the safety of Perjeta and to provide appropriate information to Health
Authorities, Healthcare Providers and patients.
For Healthcare Professionals only
1
Published by Roche Singapore Pte Ltd 1 Paya Lebar Link, # 09-03 PLQ 1 Paya Lebar Quarter, Singapore 408533
Tel: +65 6735 0550 | Fax: +65 6737 5216 M-SG-00000199-12-2020MAIN SPONSORS
PLATINUM SPONSORS
SILVER SPONSOR
E-PARTNERS
APBCS.ORG
INDEX® Conferences & Exhibitions Organization Est.
P.O. Box: 13636 | Dubai-UAE | INDEX Holding Headquarters Road # D-62 | Opposite Nad Al Hamar
Tel: +971 4 5208888 | Fax: +971 4 3384193 | Email: info@apbcs.org
8You can also read
